Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors

<div>Pretreatment: (a) PET-CT: splenomegaly and increased metabolism in the spleen are observed at diagnosis; (b) bone marrow biopsy: macrophage phagocytosing erythrocytes and neutrophils (hemophagocyte).</div>

Case Reports in Oncological Medicine

fig1

Figure 1

Figure 1: Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors 

Figure 1 | Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors 